ETNB

89Bio Inc

Add to Watchlist

Advanced Chart

7.550

+0.150(+2.030%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

7.720

Open

7.370

VWAP

7.59

Vol

1.52M

Mkt Cap

1.10B

Low

7.340

Amount

11.54M

EV/EBITDA(TTM)

Total Shares

98.38M

676.06M

EV/OCF(TTM)

P/S(TTM)

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

-0.497

-64.23%

-0.480

+0.04%

-0.502

-6.99%

Estimates Revision

The market is revising No Change the revenue expectations for 89bio, Inc. (ETNB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -13.52%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-21.22%

In Past 3 Month

Stock Price

Go Down

-13.52%

In Past 3 Month

9 Analyst Rating

214.97% Upside

Wall Street analysts forecast ETNB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ETNB is 23.78 USD with a low forecast of 11.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

2 Hold

0 Sell

Strong Buy

214.97% Upside

Current: 7.550

Low

11.00

Averages

23.78

High

37.00

214.97% Upside

Current: 7.550

Low

11.00

Averages

23.78

High

37.00

Goldman Sachs

Andrea Newkirk

Hold

Initiates

$11

2025-03-14

Reason

Goldman Sachs

Andrea Newkirk

Price Target

$11

2025-03-14

Initiates

Hold

Reason

Goldman Sachs initiated coverage of 89bio with a Neutral rating and $11 price target. 89bio is a late-stage clinical company focused on liver and cardiometabolic diseases, the analyst tells investors in a research note. While positive into the upcoming data reads on the back of "compelling" Phase 2 data and mechanistic rationale, the firm is on the sidelines ahead of the Phase 3 ENLIGHTEN-Fibrosis data in F2/F3 f non-alcoholic steatohepatitis where it believes greater clarity on pegozafermin's clinical profile is needed.

Citigroup

Geoff Meacham

Strong Buy

Initiates

$25

2025-03-13

Reason

Citigroup

Geoff Meacham

Price Target

$25

2025-03-13

Initiates

Strong Buy

Reason

Citi analyst Geoff Meacham initiated coverage of 89bio with a Buy rating and $25 price target. Healthcare policy remains a key biopharma sector uncertainty but major economic worries have underscored the defensive attributes of biotech, the analyst tells investors in a research note. The firm says that despite near-term "choppiness," a "barbell approach" to the sector still makes sense with higher-growth large caps likely able to absorb potential policy headwinds and catalyst-driven small-cap biotechs being insulated from macro uncertainties. Citi's preferred smaller caps are focused on unmet medical needs, have differentiated research and development platforms or are "clean growth stories." The firm highlights Apogee, Avidity, and Kymera as favorites.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$29 → $21

2025-02-28

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$29 → $21

2025-02-28

Reiterates

Strong Buy

Reason

Wolfe Research

Andy Chen

Buy

Initiates

n/a

2025-02-04

Reason

Wolfe Research

Andy Chen

Price Target

n/a

2025-02-04

Initiates

Buy

Reason

UBS

Eliana Merle

Strong Buy

Maintains

$25 → $38

2025-01-31

Reason

UBS

Eliana Merle

Price Target

$25 → $38

2025-01-31

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$29

2025-01-21

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$29

2025-01-21

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for 89Bio Inc (ETNB.O) is -3.59, compared to its 5-year average forward P/E of -4.70. For a more detailed relative valuation and DCF analysis to assess 89Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.70

Current PE

-3.59

Overvalued PE

-2.37

Undervalued PE

-7.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.51

Current EV/EBITDA

-1.89

Overvalued EV/EBITDA

-0.50

Undervalued EV/EBITDA

-4.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

448.25

Current PS

0.00

Overvalued PS

1500.84

Undervalued PS

-604.33